RT Journal Article
SR Electronic
T1 IMP3 Expression in Borderline Tumors of the Ovary
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 583
OP 588
VO 37
IS 2
A1 AHMED EL-BALAT
A1 NICOLE SÄNGER
A1 THOMAS KARN
A1 SVEN BECKER
A1 UWE HOLTRICH
A1 ZELAL MUALLEM
A1 RUZA ARSENIC
YR 2017
UL http://ar.iiarjournals.org/content/37/2/583.abstract
AB Background/Aim: Borderline ovarian tumors (BOTs) have a less aggressive behavior than invasive epithelial ovarian tumors. Still some patients relapse or succumb to disease. Molecular markers that reliably predict prognosis are lacking. Insulin-like growth factor II mRNA-binding protein (IMP3) has been suggested as a prognostic marker in colorectal, hepatocellular, and ovarian clear-cell carcinomas. Materials and Methods: We analyzed the expression of IMP3 by immunohistochemistry in a cohort of 140 BOT and its association with histopathological features. Results: We found no association of IMP3 expression with patients' age, FIGO stage, microinvasion, and presence of implants. In contrast, IMP3 expression correlated to mucinous subtype of BOTs (42.2% vs. 9.5% among other subtypes) (p<0.001). IMP3 expression was found to be associated with the presence of in situ carcinoma in MBOT, but not in other subtypes (p=0.021). Conclusion: Expression of IMP3 in BOT is associated with the mucinous subtype and may serve as an early indicator for the development of malignant features.